U.S. Industrials Stock News

In recent weeks, Cooper Companies has attracted attention as insiders, including senior executives, bought shares while analysts reiterated positive views ahead of the March 5 earnings release. At the same time, The London Company’s new position and expectations that earnings and revenue for the January 2026 quarter will exceed last year’s levels have reinforced market focus on Cooper’s contact lens and women’s health businesses. Next, we’ll examine how this insider buying and analyst...

If you are wondering whether Tidewater's share price still offers value or if most of the opportunity is already reflected, this article is going to focus squarely on what the numbers are saying about valuation. Tidewater's stock last closed at US$79.42, with returns of 8.2% over 7 days, 30.3% over 30 days, 52.1% year to date and 74.1% over 1 year. This naturally raises questions about how much of the story is already priced in. Recent attention around Tidewater has centred on its role in...

Oportun Financial (OPRT) has wrapped up FY 2025 with fourth quarter revenue of US$189.8 million and basic EPS of US$0.07, alongside net income of US$3.4 million. Its trailing twelve month numbers sit at US$725.2 million in revenue and EPS of US$0.53 on net income of US$25.2 million. Over recent periods the company has seen quarterly revenue move between US$174.8 million and US$194.2 million, with basic EPS ranging from a loss of US$0.75 to a profit of US$0.21. This gives investors a clearer...

If you are wondering whether Haemonetics shares are quietly offering value at around US$63.32, you are not alone. Many investors are asking the same question right now. The stock is up 3.5% over the past week, although that sits against a 4.1% decline over 30 days, a 20.8% decline year to date, and a 3.3% decline over the past year, which may have reshaped how investors think about its risk and return profile. These returns also sit alongside a 18.8% decline over three years and a 47.3%...

MBIA (MBI) has just closed out FY 2025 with fourth quarter revenue of US$13 million and a basic EPS loss of US$1.01, alongside net income from ongoing operations showing a loss of US$50 million. The company has seen quarterly revenue move from US$26 million in Q4 2024 through US$33 million and negative US$43 million in early 2024 to US$21 million, US$15 million, then US$13 million in 2025. Quarterly basic EPS has ranged from a loss of US$5.33 in Q2 2024 to losses of US$1.28, US$0.14 and...

Globant (GLOB) closed out FY 2025 with Q4 revenue of US$612.5 million and basic EPS of US$0.94, alongside net income excluding extra items of US$41.6 million, setting the tone for how the full year’s profitability story lands with investors. Over the last six reported quarters, revenue has moved in a tight band between US$611.1 million and US$642.5 million while quarterly basic EPS has ranged from a loss of US$0.05 to a high of US$1.00, reflecting shifting earnings power that puts the focus...

Smithfield Foods, NasdaqGS:SFD, plans to build a new packaged meats and fresh pork processing facility in Sioux Falls, South Dakota. The new facility is intended to replace the company’s historic existing plant in the city. The expansion is aimed at improving operational efficiency and supporting the surrounding agricultural community. For investors following NasdaqGS:SFD, this project comes with the stock trading at $24.88 and a return of 24.9% over the past year. That kind of move often...

On February 19, 2026, Live Oak Bancshares’ board declared a US$0.03 per share common dividend and a US$0.52344 per Series A preferred depositary share dividend, both payable on March 15, 2026 to shareholders of record on March 5, 2026. The simultaneous affirmation of common and higher-yielding preferred dividends underscores management’s current confidence in the bank’s capital position despite recent macro-driven pressure on regional lenders. With inflation concerns weighing on regional...

ANI Pharmaceuticals (ANIP) just posted fourth quarter FY 2025 revenue of US$247.1 million with basic EPS of US$1.56, capping a trailing twelve month stretch that saw revenue reach US$883.4 million and basic EPS of US$3.85. The company has seen revenue move from US$190.6 million and basic EPS of a US$0.55 loss in Q4 2024 to US$247.1 million and US$1.56 in Q4 2025, while trailing twelve month EPS shifted from a US$1.04 loss to a US$3.85 profit as margins turned positive. For investors, this set...

PROCEPT BioRobotics (NasdaqGM:PRCT) has overhauled its commercial model, implementing a major realignment of its sales organization and pricing strategy. The company has removed bulk purchase discounts and created a dedicated team focused on driving greater procedural adoption. These changes come alongside significant procedure growth and a reset in financial guidance, marking a key shift in how the company pursues profitability and market expansion. PROCEPT BioRobotics focuses on robotic...

Recursion Pharmaceuticals reported its first positive clinical proof-of-concept for REC-4881 in familial adenomatous polyposis. The company hit a fifth collaboration milestone with Sanofi tied to its AI driven drug discovery platform. Management extended the cash runway into early 2028, reinforcing funding visibility for ongoing programs. For investors watching NasdaqGS:RXRX, this mix of clinical and partnership progress comes alongside a share price of $3.67 and a 1-year return...

Alpha Metallurgical Resources (AMR) has wrapped up FY 2025 with fourth quarter revenue of US$520.5 million and a basic EPS loss of US$1.34, while trailing twelve month figures show revenue of about US$2.1 billion and a basic EPS loss of US$4.75. Over the past few quarters, revenue has moved from US$617.3 million in Q4 2024 to US$520.5 million in Q4 2025, with quarterly EPS shifting from a loss of US$0.16 in Q4 2024 to a loss of US$1.34 in Q4 2025. Investors may weigh the recent margin trends...

Cinemark Holdings has already reported fourth-quarter 2025 results showing revenue of US$776.3 million and net income of US$34.1 million, alongside full-year 2025 revenue of US$3.12 billion and net income of US$138.2 million. Despite lower quarterly earnings than the prior year, Cinemark’s board maintained a US$0.09 quarterly dividend and completed a US$75 million share repurchase of 3,136,810 shares, signaling continued capital returns. We’ll now examine how Cinemark’s latest earnings...

Danaher (NYSE:DHR) has agreed to acquire Masimo Corporation in a cash and stock deal valued at $9.9b. Masimo, a specialty diagnostics leader, will operate as a standalone business within Danaher’s Diagnostics segment. The transaction is intended to expand Danaher’s presence in healthcare technology and diagnostic solutions. Danaher, trading at around $209.94 per share, is pursuing one of its largest deals as it looks to deepen its role in diagnostics. The stock is up 1.7% over the past year...

Smart Sand (SND) has wrapped up FY 2025 with fourth quarter revenue of US$86.0 million, basic EPS of US$0.03 and net income of US$1.2 million, setting the stage for investors to reassess how the business is converting its top line into profits. Over the past few quarters, the company has seen revenue move between US$65.6 million and US$92.8 million per quarter, while basic EPS has ranged from a loss of US$0.62 to a profit of US$0.55, giving a wide view of how earnings have tracked against...

If you are wondering whether Primerica’s share price reflects its underlying value, this article walks through what the current numbers can and cannot tell you about the stock. Over shorter periods the picture has been mixed, with returns of a 2.9% decline over 7 days, a 2.2% decline over 30 days, a 2.0% decline year to date and an 11.1% decline over 1 year, set against longer term returns of 40.7% over 3 years and 86.8% over 5 years. Recent news coverage has largely focused on Primerica’s...

TTEC Holdings (TTEC) closed out FY 2025 with fourth quarter revenue of US$570 million and a basic EPS loss of US$3.55, alongside a net loss of US$172 million, setting a challenging tone around profitability. Over the last six reported quarters, revenue has moved in a tight band between US$513 million and US$570 million, while quarterly EPS has swung from a small profit of US$0.03 in early 2025 to losses. On a trailing twelve month view, EPS sits at a loss of US$3.99 on revenue of about US$2.1...

Organon (OGN) is back on investors radar after releasing detailed sub analysis data from its Phase 3 ADORING trials, which showed that VTAMA cream improved sleep outcomes in children with atopic dermatitis and their families. See our latest analysis for Organon. Despite the encouraging VTAMA data, Organon’s recent share price performance has been weak, with a 30 day share price return of negative 18.0% and a 1 year total shareholder return decline of 50.6%, suggesting sentiment remains...

CoreWeave (CRWV) FY 2025 results: rapid top line expansion alongside ongoing losses CoreWeave (CRWV) has just posted its FY 2025 numbers, with fourth quarter revenue of US$1.6b and a basic EPS loss of US$0.83, alongside trailing twelve month revenue of US$5.1b and a loss of US$2.68 per share. Over the past six reported quarters, the company has seen revenue move from US$583.9m in Q3 2024 to US$1.6b in Q4 2025. Quarterly basic EPS has ranged from a loss of US$1.82 in Q3 2024 to a loss of...

Personalis (PSNL) just posted its FY 2025 figures with Q4 revenue of about US$17.3 million and a basic EPS loss of roughly US$0.26, alongside a trailing twelve month EPS loss of about US$0.91 on revenue of roughly US$69.6 million. Over recent quarters, the company has seen quarterly revenue move between about US$14.5 million and US$20.6 million, while quarterly basic EPS losses have ranged from roughly US$0.18 to US$0.26. This keeps the focus squarely on when scale can start to ease those...

Via Transportation (VIA) FY 2025 earnings recap Via Transportation (VIA) just closed out FY 2025 with Q4 revenue of US$118.9 million and a basic EPS loss of US$0.28, while trailing twelve month revenue reached US$434.3 million against a full year EPS loss of US$1.21. The company has seen quarterly revenue move from US$83.3 million in Q3 2024 to US$118.9 million in Q4 2025, as basic EPS ranged between a loss of US$1.70 and US$0.28 over the same stretch, and over the last year management...

Puma Biotechnology (PBYI) closed FY 2025 with Q4 revenue of US$75.5 million and basic EPS of US$0.27, alongside net income of US$13.4 million. Its trailing 12 month revenue came in at US$228.4 million with basic EPS of US$0.62 and net income of US$31.1 million. Over recent periods, the company has seen quarterly revenue range from US$46.0 million to US$80.5 million and basic EPS move between US$0.06 and US$0.98. This gives investors a clear view of how earnings scale with top line...

Emergent BioSolutions (EBS) has just wrapped up FY 2025 with Q4 revenue of US$148.7 million and basic EPS of a US$1.04 loss, capping a year in which quarterly revenue ranged from US$140.9 million to US$231.1 million and EPS swung between a profit of US$1.25 and a loss of US$0.22. Over the trailing 12 months to Q4 2025, the company recorded total revenue of US$742.9 million and basic EPS of US$0.98. This leaves investors to weigh improving headline profitability alongside still uneven...

PRA Group (PRAA) closed out FY 2025 with Q4 revenue of US$333.4 million and basic EPS of US$1.46, while the trailing 12 month picture shows total revenue of about US$1.2 billion and a basic EPS loss of US$7.79. The company has seen quarterly revenue move from US$293.2 million in Q4 2024 to US$333.4 million in Q4 2025, with basic EPS shifting from US$0.47 to US$1.46 over the same period, alongside a wider loss on a trailing 12 month basis of US$305.1 million. Margins look compressed on the...